Liver enzyme effects of medicinal cannabis in advanced cancer: a substudy of two randomised trials
In patients with advanced malignancy enrolled in two clinical trials, medicinal cannabis products did not have a significant adverse impact on ALT or AST levels during the first 4 weeks of use at the doses studied.
Authors
- Anita Pelecanos (ORCID: https://orcid.org/0000-0003-0197-4504)
- Ristan M. Greer (ORCID: https://orcid.org/0000-0002-1574-4729)
- Georgie Huggett
- Luke Scarborough
- Taylan Gurgenci (ORCID: https://orcid.org/0000-0001-9695-9109)
- Janet Hardy (ORCID: https://orcid.org/0000-0003-1127-9951)
- Phillip D. Good (ORCID: https://orcid.org/0000-0002-8198-0375)
- Lachlan Webb
Institutions
- Mater Health Services (AU)
- The University of Queensland (AU)
- QIMR Berghofer Medical Research Institute (AU)
- Mater Misericordiae Hospital (AU)
- Mater Research (AU)
- St Vincent’s Private Hospital Brisbane (AU)
- Hospice UK (GB)
Publication Details
- Journal
- BMJ Supportive & Palliative Care
- Published
- 2025-12-21
- DOI
- https://doi.org/10.1136/spcare-2025-005837
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00